Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: Results of a retrospective Italian multicentre survey

Digestive and Liver Disease

Volumn 35, Issue 5, 2003, Pages 325-331

  Okolicsanyi, L ^a,j   Groppo, M ^a   Floreani, A ^b   Morselli Labate, A M ^b   Rusticali, A G ^c   Battocchia, A ^d   Colombo, M ^e   Galatola, G ^f   Gasbarrini, G ^g   Podda, M ^h   Ricci, G ⁱ   Rosina, F ^f   Zuin, M ^h  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Sanofi Winthrop SpA   (Italy)

^d Main Civil Hospital   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

^f MAURIZIANO HOSPITAL   (Italy)

^g CATHOLIC UNIVERSITY   (Italy)

^h SAN PAOLO HOSPITAL   (Italy)

ⁱ SAPIENZA UNIVERSITY OF ROME   (Italy)

^j UNIVERSITY OF PADOVA   (Italy)

more..

Author keywords

Medical treatment; Primary sclerosing cholangitis; Ursodeoxycholic acid

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GAMMA GLUTAMYLTRANSFERASE; URSODEOXYCHOLIC ACID; CHOLAGOGUE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFICACY; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; ITALY; JAUNDICE; LIVER FUNCTION TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIMARY SCLEROSING CHOLANGITIS; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TREATMENT OUTCOME; WEIGHT REDUCTION; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; SCLEROSING CHOLANGITIS;

ADULT; AGED; CHOLAGOGUES AND CHOLERETICS; CHOLANGITIS, SCLEROSING; FEMALE; HUMANS; ITALY; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 0142119481     PISSN: 15908658     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1590-8658(03)00076-8     Document Type: Article

References (35)

1. Okolicsanyi L, Fabris L. Diagnostic approach to primary sclerosing cholangitis: open questions. Ital J Gastroenterol 1991;23:436-41.
2. Olsson R, Broomé U, Danielsson A, Hagerstand I, Jarnerot G, Loof L, et al. Colchicine treatment of primary sclerosing cholangitis. Gastroenterology 1995;108:1199-203.
3. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. Gastroenterology 1994;106:494-9.
4. LaRusso NF, Wiesner RH, Ludwig J, MacCarthy RL, Beaver SJ, Zinsmeister AR. Prospective trial of penicillamine in primary sclerosing cholangitis. Gastroenterology 1988;95:1036-42.
5. Angulo P, Bharucha AE, Jorgensen RA, Desotel CK, Sandborn WJ, LaRusso NF, et al. Oral nicotine in treatment of primary sclerosing cholangitis: a pilot study. Dig Dis Sci 1999;44:602-7.
6. Van Thiel DH, Carrol P, Abu-Elmagd K, Rodriguez-Rilo H, Irish W, McMichael J, et al. Tacrolimus (FK 506), a treatment for primary sclerosing cholangitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:455-9.
7. O'Brien C, Senior JR, Arora-Mirchandani R, Batta AK, Salen G. Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: a 30-month pilot study. Hepatology 1991;14:838-47.
8. Beuers U, Splengler U, Kruis W, Aydemir U, Wiebecke B, Heldwein W et al. Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial. J Hepatol 1992;16:707-14.
9. Chazouilleres O, Poupon R, Capron JP, Metman EH, Dhumeaux D, Amouretti M, et al. Ursodeoxycholic acid for primary sclerosing cholangitis. J Hepatol 1990;11:120-3.
10. Stiehl A, Walker S, Stiehl L, Rudolph G, Hoffmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. J Hepatol 1994;20:57-64.
11. Lindor KD for the Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Group. Ursodiol for primary sclerosing cholangitis. New Engl J Med 1997;336:691-5.
12. Schramm C, Schirmacher P, Helmreich-Becker I, Gerken G, Zum Buschenfelde KH, Lohse AW. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. A case series. Ann Intern Med 1999;131:943-6.
13. Okolicsanyi L, Fabris L, Viaggi S, Carulli N, Podda M, Ricci G on behalf of the Italian PSC Study Group. Primary sclerosing cholangitis: clinical presentation, natural history and prognostic variables. An Italian multicenter study. Eur J Gastroenterol Hepatol 1996;8:685-91.
14. Escorsell A, Parés A, Rodés J, Solis-Herruzo JA, Miras M, De la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. J Hepatol 1994;21:787-91.
15. Ludwig JH. Surgical pathology of the syndrome of primary sclerosing cholangitis. Am J Surg Pathol 1989;13:43-9.
16. Kim WR, Therneau TM, Wiesner RH, Poterucha JJ, Benson JT, Malinchoc M, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000;75:688-94.
17. Siegel S, editor, Nonparametric statistics for the behavioural sciences, New York: McGraw-Hill, 1956.
18. Snedecor GW, Cochran WG, editors, Statistical methods, 8th ed., Ames, IA: Iowa University Press, 1989.
19. Haberman SJ, editor, Analysis of qualitative data, vol. 1, New York: Academic Press, 1978.
20. Norusis MJ. SPSS/PC+ base system user's guide, version 5.0. Chicago, IL: SPSS Inc, 1992.
21. Norusis MJ. SPSS/PC+ advanced statistics, version 5.0. Chicago, IL: SPSS Inc, 1992.
22. Rodrigues CMP, Fan G, Ma X, Kren BT, Steer CJ. A novel role of ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998;101:2790-9.
23. Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990;11:12-5.
24. Van Milligen De Wit AW, Kuiper H, Camoglio L, Van Bracht J, Jones EA, Tygat GN, et al. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis? Eur J Gastroenterol Hepatol 1999;11:129-36.
25. Angulo P, Dickson ER, Therneau TM, Jorgensen RA, Smith C, DeSotel CK, et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999;30:830-5.
26. Van Hoogstraten HJF, Desmet MBM, Renooij W, Bred JGS, Engels LGJB, Den Ouden-Muller JW, et al. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Aliment Pharmacol Ther 1998;12:965-71.
27. Verma A, Jazrawi RP, Ahmed HA, Davis T, Bland JM, Benson M, et al. Potimum dose of ursodeoxycholic acid in primary biliary cirrhosis. Eur J Gastroenterol Hepatol 1999;11:1069-76.
28. Podda M, Ghezzi C, Battezzati PM, Bertolini E, Crosignani A, Petroni ML, et al. Effect of different doses of ursodeoxycholic acid in chronic liver disease. Dig Dis Sci 1989;34:59S-65S.
29. Walker S, Stiehl A, Raedsch R, Kloters P, Kommerell B. Absorption of urso- and chenodeoxycholic acid and their taurine and glycine conjugates in rat ileum, ileum, and colon. Digestion 1985;32:47-52.
30. Van Hoogstraten HJ, Wolfhagen FH, Van De Meeberg PC, Kuiper H, Nix GA, Becx MC, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J Hepatol 1998;29:417-23.
31. Mitchell SA, Bansi DS, Hunt N, v Bergmann K, Fleming KA, Chapman RW. A preliminary trial of high-dose Ursodeoxycholic acid in primary sclerosing cholangitis. Gastroenterology 2001;121:900-7.
32. Harnois DM, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. Am J Gastroenterol 2001;96:1558-62.
33. van den Berg A, Jansen PL. Pathogenesis and medical therapy of primary sclerosing cholangitis. Any news? Eur J Gastroenterol Hepatol 1999;11:121-4.
34. Angulo P, Peter JB, Gershwin ME, DeSotel CK, Shoenfeld Y, Ahmed AE, et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J Hepatol 2000;32:182-7.
35. Lee Y-M, Kaplan MM on behalf of the Practice Guideline Committee of the ACG. Management of primary sclerosing cholangitis. Am J Gastroenterol 2002;97:528-34.